Met	O
amplification	O
and	O
tumor	B-Cancer
progression	O
in	O
Cdkn2a	B-Cell
-	I-Cell
deficient	I-Cell
melanocytes	I-Cell
.	O

While	O
many	O
genetic	O
alterations	O
have	O
been	O
identified	O
in	O
melanoma	B-Cancer
,	O
the	O
relevant	O
molecular	O
events	O
that	O
contribute	O
to	O
disease	O
progression	O
are	O
poorly	O
understood	O
.	O

Most	O
primary	B-Cancer
human	I-Cancer
melanomas	I-Cancer
exhibit	O
loss	O
of	O
expression	O
of	O
the	O
CDKN2A	O
locus	O
in	O
addition	O
to	O
activation	O
of	O
the	O
canonical	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
signaling	O
pathway	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
Cdkn2a	O
-	O
deficient	O
mouse	O
melanocyte	B-Cell
cell	I-Cell
line	I-Cell
to	O
screen	O
for	O
secondary	O
genetic	O
events	O
in	O
melanoma	B-Cancer
tumor	I-Cancer
progression	O
.	O

Upon	O
investigation	O
,	O
intrachromosomal	B-Cellular_component
gene	O
amplification	O
of	O
Met	O
,	O
a	O
receptor	O
tyrosine	O
kinase	O
implicated	O
in	O
melanoma	B-Cancer
progression	O
,	O
was	O
identified	O
in	O
Cdkn2a	B-Cancer
-	I-Cancer
deficient	I-Cancer
tumors	I-Cancer
.	O

RNA	O
interference	O
targeting	O
Met	O
in	O
these	O
tumor	B-Cell
cells	I-Cell
resulted	O
in	O
a	O
significant	O
delay	O
in	O
tumor	B-Cancer
growth	O
in	O
vivo	O
compared	O
with	O
the	O
control	O
cells	B-Cell
.	O

MET	O
expression	O
is	O
rarely	O
detected	O
in	O
primary	B-Cancer
human	I-Cancer
melanoma	I-Cancer
but	O
is	O
frequently	O
observed	O
in	O
metastatic	B-Cancer
disease	I-Cancer
.	O

This	O
study	O
validates	O
a	O
role	O
for	O
Met	O
activation	O
in	O
melanoma	B-Cancer
tumor	I-Cancer
progression	O
in	O
the	O
context	O
of	O
Cdkn2a	O
deficiency	O
.	O

